These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35053227)

  • 1. Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups.
    Shimada H; Ikegaki N
    Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
    Okamatsu C; London WB; Naranjo A; Hogarty MD; Gastier-Foster JM; Look AT; LaQuaglia M; Maris JM; Cohn SL; Matthay KK; Seeger RC; Saji T; Shimada H
    Pediatr Blood Cancer; 2009 Oct; 53(4):563-9. PubMed ID: 19530234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.
    Veschi V; Petroni M; Bartolazzi A; Altavista P; Dominici C; Capalbo C; Boldrini R; Castellano A; McDowell HP; Pizer B; Frati L; Screpanti I; Gulino A; Giannini G
    Cell Death Dis; 2014 Mar; 5(3):e1100. PubMed ID: 24603328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathology of peripheral neuroblastic tumors].
    Wang L; He LJ; Shimada H
    Zhonghua Bing Li Xue Za Zhi; 2012 Apr; 41(4):283-8. PubMed ID: 22800533
    [No Abstract]   [Full Text] [Related]  

  • 7. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Shimada H; Umehara S; Monobe Y; Hachitanda Y; Nakagawa A; Goto S; Gerbing RB; Stram DO; Lukens JN; Matthay KK
    Cancer; 2001 Nov; 92(9):2451-61. PubMed ID: 11745303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1 in pediatric neuroblastic tumors: A microarray analysis.
    Fagone P; Nicoletti F; Vecchio GM; Parenti R; Magro G
    Acta Histochem; 2015 Oct; 117(8):820-3. PubMed ID: 26510683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of delta-like gene and protein in neuroblastoma, ganglioneuroblastoma and ganglioneuroma.
    Hsiao CC; Huang CC; Sheen JM; Tai MH; Chen CM; Huang LL; Chuang JH
    Mod Pathol; 2005 May; 18(5):656-62. PubMed ID: 15605081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.
    Tabyaoui I; Tahiri-Jouti N; Serhier Z; Bennani-Othmani M; Sibai H; Itri M; Benchekroun S; Zamiati S
    Diagn Pathol; 2013 Feb; 8():39. PubMed ID: 23445749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The International Neuroblastoma Pathology Classification (the Shimada system).
    Shimada H; Ambros IM; Dehner LP; Hata J; Joshi VV; Roald B; Stram DO; Gerbing RB; Lukens JN; Matthay KK; Castleberry RP
    Cancer; 1999 Jul; 86(2):364-72. PubMed ID: 10421273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathologic features of peripheral neuroblastic tumors].
    Yang BF; Fu LB; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):305-10. PubMed ID: 24004586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation between typing of peripheral neuroblastic tumors and prognosis: a clinicopathologic study of 135 cases].
    YIN MZ; ZHANG ZD; MA J; SHEN P; CHEN JF; ZHANG HZ
    Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):151-5. PubMed ID: 21575383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell profiling of peripheral neuroblastic tumors identifies an aggressive transitional state that bridges an adrenergic-mesenchymal trajectory.
    Yuan X; Seneviratne JA; Du S; Xu Y; Chen Y; Jin Q; Jin X; Balachandran A; Huang S; Xu Y; Zhai Y; Lu L; Tang M; Dong Y; Cheung BB; Marshall GM; Shi W; Carter DR; Zhang C
    Cell Rep; 2022 Oct; 41(1):111455. PubMed ID: 36198269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of ALK and GD2 Expression in Neuroblastoma.
    Aygün Z; Batur Ş; Emre Ş; Celkan T; Özman O; Comunoglu N
    Fetal Pediatr Pathol; 2019 Aug; 38(4):326-334. PubMed ID: 30955398
    [No Abstract]   [Full Text] [Related]  

  • 16. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
    Nakazawa A
    Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.
    Wilzén A; Krona C; Sveinbjörnsson B; Kristiansson E; Dalevi D; Øra I; De Preter K; Stallings RL; Maris J; Versteeg R; Nilsson S; Kogner P; Abel F
    Mol Cancer; 2013 Jul; 12(1):70. PubMed ID: 23835063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.
    Tabyaoui I; Tahiri-Jouti N; Serhier Z; El Maani K; Cherkaoui S; Al Zemmouri M; Othmani MB; Zamiati S
    Diagn Mol Pathol; 2013 Jun; 22(2):112-8. PubMed ID: 23628823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients.
    Banelli B; Bonassi S; Casciano I; Mazzocco K; Di Vinci A; Scaruffi P; Brigati C; Allemanni G; Borzì L; Tonini GP; Romani M
    Int J Cancer; 2010 Feb; 126(3):656-68. PubMed ID: 19626586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular.
    Peuchmaur M; d'Amore ES; Joshi VV; Hata J; Roald B; Dehner LP; Gerbing RB; Stram DO; Lukens JN; Matthay KK; Shimada H
    Cancer; 2003 Nov; 98(10):2274-81. PubMed ID: 14601099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.